Showing results (331-340 of 675) with videos related to
Sort By:
Pageof 68
Journal of the National Cancer Institute|June 6, 2002
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRODavid M Euhus, Kristin C Smith, Linda Robinson, et al.Clinical Genitourinary Cancer|May 7, 2016
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial CancerPeter H O'Donnell, Shaheen Alanee, Kelly L Stratton, et al.Cancer Research|December 18, 2004
Estrogen receptor genotypes and haplotypes associated with breast cancer riskBert Gold, Francis Kalush, Julie Bergeron, et al.Breast Cancer Research and Treatment|February 6, 2013
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?Steven A Narod, Kelly Metcalfe, Henry T Lynch, et al.The American Journal of Gastroenterology|February 25, 2026
Colorectal neoplasia rates in Li Fraumeni SyndromeSophia R Spiegel, Caitlin Orr, Nicolas U Edgar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2Nadine M Tung, Mark E Robson, Tianyu Li, et al.Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.Breast Cancer Research and Treatment|May 15, 2014
Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer familiesAngela G Arnold, Ebunoluwa Otegbeye, Megan Harlan Fleischut, et al.Cancer|February 14, 2014
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2Sarah A Jackson, Andrew A Davis, Jun Li, et al.Human Mutation|June 3, 2020
Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelinesCristina Fortuno, Jessica Mester, Tina Pesaran, et al.Pageof 68